The most common, expected, and reversible treatment-emergent adverse event associated with the agent was cytokine release syndrome.
Kristie L. Kahl
Overall survival (OS) benefit derived from frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer was further improved after at least 12 months of follow-up.
Frontline treatment with nivolumab plus ipilimumab induced durable and long-term efficacy, compared with chemotherapy, in patients with advanced non-small cell lung cancer, regardless of PD-L1 expression.
The FDA has approved brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer, as detected by an FDA-approved test.
The VEGF TKI induced durable responses and favorable tolerability in patients with relapsed/refractory RCC.
Treatment with olaparib in the maintenance setting extended overall survival by more than a year in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations.
Researchers showed that integration of a comprehensive geriatric assessment with geriatrician-led management care improved quality of life for older adults with cancer.
The FDA approved the first therapy to treat cancers with rearranged during transfection (RET) gene alterations.
The FDA approved an additional recommended dose of 400 mg pembrolizumab (Keytruda) every 6 weeks across all adult indications.
The FDA approved the combination use of encorafenib and cetuximab for the treatment of adult patients with BRAFV600E-positive metastatic colorectal cancer.